C2N Diagnostics

C2N Diagnostics is a company focused on the development and commercialization of diagnostics for neurodegenerative conditions, with a primary focus on Alzheimer's disease. The company's core offering is the Precivity™ portfolio of blood tests, including the PrecivityAD™ and PrecivityAD2™ assays. These tests are designed for individuals aged 55 and older who are experiencing cognitive impairment, providing a less invasive and more cost-effective alternative to traditional diagnostic methods like PET scans and cerebrospinal fluid analysis.

C2N's diagnostic approach is based on high-resolution mass spectrometry to measure the concentration of specific proteins and peptides in the blood, which are then analyzed using proprietary algorithms to predict the likelihood of Alzheimer's disease pathology. This technology aims to facilitate earlier and more accurate diagnosis, which is critical for timely intervention and management of the disease.

The company operates in the clinical diagnostics market and has secured partnerships to expand its reach, such as a multi-year agreement with Unilabs for the exclusive distribution of its Precivity tests in Europe. C2N has also achieved regulatory milestones, including medical device certification from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its PrecivityAD2 blood test. The company is also developing a more comprehensive Brain Health Panel to assess multiple indicators of Alzheimer's and other neurological disorders.

Keywords: Alzheimer's diagnostics, blood test, neurodegeneration, mass spectrometry, clinical diagnostics, brain health, PrecivityAD, biomarkers, diagnostic solutions, neurology